| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yong Min Ahn, Kyu Young Lee, Chul-Eung Kim, Jae-Jin Kim, Dae-Yeob Kang, Tae-Youn Jun, Jin Sook Choi, In-Won Chung, Se Hyun Kim, Samuel S-H Hwang, Yong Sik Ki. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. Journal of clinical psychopharmacology. vol 29. issue 2. 2009-08-18. PMID:19512972. |
changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. |
2009-08-18 |
2023-08-12 |
Not clear |
| Yong Min Ahn, Kyu Young Lee, Chul-Eung Kim, Jae-Jin Kim, Dae-Yeob Kang, Tae-Youn Jun, Jin Sook Choi, In-Won Chung, Se Hyun Kim, Samuel S-H Hwang, Yong Sik Ki. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. Journal of clinical psychopharmacology. vol 29. issue 2. 2009-08-18. PMID:19512972. |
we examined short- and long-term changes in neurocognitive functions in patients with schizophrenia who were either started or switched to amisulpride in comparison with the normal controls. |
2009-08-18 |
2023-08-12 |
Not clear |
| Matthias J Müller, F X Eich, B Regenbogen, J Sachse, S Härtter, C Hiemk. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. Journal of psychopharmacology (Oxford, England). vol 23. issue 3. 2009-07-09. PMID:18562411. |
amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. |
2009-07-09 |
2023-08-12 |
Not clear |
| Matthias J Müller, F X Eich, B Regenbogen, J Sachse, S Härtter, C Hiemk. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. Journal of psychopharmacology (Oxford, England). vol 23. issue 3. 2009-07-09. PMID:18562411. |
because of a unique pharmacodynamic profile, amisulpride seems appropriate for treatment of elderly patients with schizophrenia. |
2009-07-09 |
2023-08-12 |
Not clear |
| Matthias J Müller, F X Eich, B Regenbogen, J Sachse, S Härtter, C Hiemk. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. Journal of psychopharmacology (Oxford, England). vol 23. issue 3. 2009-07-09. PMID:18562411. |
in a large-scale naturalistic therapeutic drug monitoring study, daily amisulpride dose, trough and dose-corrected amisulpride plasma levels, co-medication, clinical effectiveness (cgi) and side effects (uku) were compared between age groups in 395 patients with schizophrenia or schizoaffective disorder (46% women; mean age 39.1 +/- 14.2 years, range 18-83 years) under amisulpride therapy. |
2009-07-09 |
2023-08-12 |
Not clear |
| Yi-Wei Yeh, Chih-Kang Chen, San-Yuan Huang, Shin-Chang Kuo, Chun-Yen Chen, Chih-Lun Che. Successful treatment with amisulpride for the progression of olfactory reference syndrome to schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 33. issue 3. 2009-06-16. PMID:19224708. |
successful treatment with amisulpride for the progression of olfactory reference syndrome to schizophrenia. |
2009-06-16 |
2023-08-12 |
Not clear |
| M Riedel, F X Eich, H J Mölle. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. European psychiatry : the journal of the Association of European Psychiatrists. vol 24. issue 3. 2009-06-10. PMID:19070995. |
the primary objective of this randomised, active-controlled, parallel group, double-blind study was to evaluate the tolerability of treatment with either amisulpride or risperidone in elderly patients with schizophrenia aged over 65 years; evaluation of efficacy was a secondary objective. |
2009-06-10 |
2023-08-12 |
Not clear |
| Judit Harangozó, Adrienn Slezák, Kinga Borsos, Orsolya Németh, Gábor Csukl. [Costs of treatment in patients with schizophrenia switched to amisulpride--one-year follow-up]. Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata. vol 23. issue 6. 2009-04-10. PMID:19218628. |
[costs of treatment in patients with schizophrenia switched to amisulpride--one-year follow-up]. |
2009-04-10 |
2023-08-12 |
Not clear |
| Judit Harangozó, Adrienn Slezák, Kinga Borsos, Orsolya Németh, Gábor Csukl. [Costs of treatment in patients with schizophrenia switched to amisulpride--one-year follow-up]. Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata. vol 23. issue 6. 2009-04-10. PMID:19218628. |
in our present research we have studied the costs associated with switching schizophrenia patients to amisulpride as well as the efficacy of amisulpride treatment. |
2009-04-10 |
2023-08-12 |
Not clear |
| Ying-Yeh Chen, Ming-Chyi Huang, Kevin Chien-Chang W. Weight gain in a patient with schizophrenia switched from quetiapine to amisulpride. Psychiatry and clinical neurosciences. vol 62. issue 5. 2009-02-27. PMID:18950385. |
weight gain in a patient with schizophrenia switched from quetiapine to amisulpride. |
2009-02-27 |
2023-08-12 |
Not clear |
| J Cordes, A Sinha-Röder, K G Kahl, J Malevani, J Thuenker, C Lange-Asschenfeldt, H Hauner, M W Agelink, A Klimk. [Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics]. Fortschritte der Neurologie-Psychiatrie. vol 76. issue 12. 2009-02-09. PMID:18924059. |
extensive, selective literature review of 2500 articles from the last years (up to december 2007) predominantly from medline and cochrane, using as search terms "antipsychotic or schizophrenia or individual drug names (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone)" and the terms "bmi, weight gain, metabolic syndrome, diabetes, lipid(s), cholesterol, triglycerides" was conducted. |
2009-02-09 |
2023-08-12 |
Not clear |
| Ying-Chieh Wang, Cheryl C H Yang, Ya-Mei Bai, Terry B J Ku. Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine. 3-month follow-up. Neuropsychobiology. vol 57. issue 4. 2008-12-30. PMID:18679039. |
in this study, we used a computer-assisted 5-min measurement of resting heart rate variability (hrv) in schizophrenia patients who were switched to atypical antipsychotic agents (amisulpride and olanzapine) due to severe side effects (tardive dyskinesia). |
2008-12-30 |
2023-08-12 |
human |
| E M Meisenzahl, G Schmitt, G Gründer, S Dresel, T Frodl, C la Fougère, J Scheuerecker, M Schwarz, R Boerner, J Stauss, K Hahn, H-J Mölle. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry. vol 41. issue 5. 2008-12-18. PMID:18763218. |
amisulpride appears to be an effective atypical agent for treating schizophrenia in a dose-dependent manner. |
2008-12-18 |
2023-08-12 |
Not clear |
| Luca Pani, José M Villagrán, Vassilis P Kontaxakis, Köksal Alpteki. Practical issues with amisulpride in the management of patients with schizophrenia. Clinical drug investigation. vol 28. issue 8. 2008-10-17. PMID:18598092. |
practical issues with amisulpride in the management of patients with schizophrenia. |
2008-10-17 |
2023-08-12 |
Not clear |
| Luca Pani, José M Villagrán, Vassilis P Kontaxakis, Köksal Alpteki. Practical issues with amisulpride in the management of patients with schizophrenia. Clinical drug investigation. vol 28. issue 8. 2008-10-17. PMID:18598092. |
amisulpride is an atypical antipsychotic with a significantly greater effect size than first-generation, typical antipsychotics, and efficacy at least similar to that of olanzapine and risperidone in large-scale clinical trials in schizophrenia. |
2008-10-17 |
2023-08-12 |
Not clear |
| Luca Pani, José M Villagrán, Vassilis P Kontaxakis, Köksal Alpteki. Practical issues with amisulpride in the management of patients with schizophrenia. Clinical drug investigation. vol 28. issue 8. 2008-10-17. PMID:18598092. |
amisulpride may be particularly suitable for clozapine-augmentation therapy in patients with refractory schizophrenia. |
2008-10-17 |
2023-08-12 |
Not clear |
| Luca Pani, José M Villagrán, Vassilis P Kontaxakis, Köksal Alpteki. Practical issues with amisulpride in the management of patients with schizophrenia. Clinical drug investigation. vol 28. issue 8. 2008-10-17. PMID:18598092. |
the pharmacological and clinical profiles of amisulpride suggest that this agent is a viable clinical option when a change of antipsychotic therapy is required in patients with schizophrenia because of lack of efficacy, adverse events and poor adherence to treatment, or for augmentation of clozapine in treatment-resistant illness. |
2008-10-17 |
2023-08-12 |
Not clear |
| Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Su-Jin Yang, Michael Y Hwang, Jin-Sang Yoo. Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. Journal of clinical psychopharmacology. vol 28. issue 3. 2008-09-11. PMID:18480697. |
amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. |
2008-09-11 |
2023-08-12 |
Not clear |
| Matthew J Lynch, Jessica Woods, Natalia George, Dimitri Gerostamoulo. Fatality due to amisulpride toxicity: a case report. Medicine, science, and the law. vol 48. issue 2. 2008-07-22. PMID:18533580. |
amisulpride is an atypical antipsychotic agent effective in the treatment of schizophrenia. |
2008-07-22 |
2023-08-12 |
Not clear |
| H-J Assion, H Reinbold, S Lemanski, M Basilowski, G Jucke. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. vol 41. issue 1. 2008-04-11. PMID:18203048. |
amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. |
2008-04-11 |
2023-08-12 |
Not clear |